Tyrosine Phosphatase Inhibitors As New Immunomodulators

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 21914
Amount: $49,834.00
Phase: Phase I
Program: SBIR
Awards Year: 1993
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Biomol Research Laboratoryt
5166 Campus Drive, Plymouth Meeting, PA, 19462
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Robert E. Zipkin
 (610) 941-0430
Business Contact
Phone: () -
Research Institution
N/A
Abstract
The goal of the research is to develop a potent pharmacologically useful inhibitor of the CD45 protein tyrosine phosphatase. CD45 is a transmembrane protein having a highly glycosylated extracellular region and a cytosolic domain which possesses tyrosine phosphatase activity. CD45 plays a critical role in the activation of both T- and B-lymphocytes, thus, inhibitors of CD45 may represent new immunomodulators or anti-inflammatory drugs. We will l) design and synthesize novel inhibitors of the CD45 protein tyrosine phosphatase based on a nonhydrolyzable pseudosubstrate approach, 2) evaluate the new compounds as inhibitors in an in vitro assay. The compounds developed in these studies will greatly increase our knowledge of the structure-activity relationships for protein tyrosine phosphatase inhibitors and may lead to the development of new research tools and therapeutics.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government